Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights
August 08, 2017 16:06 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma
August 07, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017
August 02, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference
June 14, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma
June 07, 2017 06:45 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting
June 05, 2017 06:45 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
May 10, 2017 06:59 ET
|
Calithera Biosciences, Inc.
Study to evaluate potential of CB-839 plus Opdivo to target immunosuppressive cancer metabolism in the tumor microenvironmentCompanies have ongoing collaboration evaluating clear cell renal cell...
Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights
May 09, 2017 16:06 ET
|
Calithera Biosciences, Inc.
-Strong quarter-end cash position of $207.1 million supports advancement of multiple clinical development programs-Calithera to Host Conference Call Today at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern...
Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
May 03, 2017 07:30 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
CB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting
April 20, 2017 10:32 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...